They could be the cause of cancer relapse—but may also offer new approaches to treatment.
Susan YoungFollow @twitterapi
I’m the biomedicine editor for MIT Technology Review. I look for stories where technology stands to improve human health or advance our understanding of the human condition.
I joined MIT Technology Review in March 2012 after a brief stint in the Washington, D.C., news bureau of the scientific journal Nature. Before I ventured to the East Coast, I spent several years in the San Francisco Bay Area as a doctoral student in molecular biology and one whirlwind year in science-writing boot camp in Santa Cruz.
In California, I wrote for the Stanford University press offices, the Multiple Sclerosis Discovery Forum, and the Salinas Californian newspaper. I grew up in a small town in eastern Texas, surrounded by bird song, rolling cattle fields, and lanky pine trees. When I’m not exploring health tech, you will probably find me cooking or giggling over an exceptional LOLcat.
Susan Young's Stories
One startup, H3 Biomedicines, uses genome data to design drugs aimed at small groups of patients.
The new study, the first to demonstrate optogenetics in primate behavior, inches the technology closer to the clinic.
Triple-combo would be easier and faster than existing treatments and could fight drug-resistant strains.
Amyloid-recognizing drug has no effect in patients with a high-risk genetic background.
StemCells Inc. hopes a clinical trial of its proprietary stem cells in rodents will lead to a clinical trial with Alzheimer's patients.
In a small trial, patients given an existing drug showed no cognitive decline over three years.
A daily dose of Gilead's Truvada reduces infection in high-risk, uninfected men.
A biotech company founded by Craig Mello, codiscoverer of RNAi, brings its first self-delivering interfering RNA to clinical trial.
The personal genetics company purchased disease-community website CureTogether earlier this week.